RESEARCH PAPER

AI-Driven Optimisation of Nanoparticle-Based Drug Delivery Systems

Anber Abraheem Shlash Mohammad[1], Suleiman Ibrahim Mohammad[2,3], Asokan Vasudevan[4,5], Badrea Al Oraini[6], Sultan Alaswad Alenazi[7]

[1]Digital Marketing Department, Faculty of Administrative and Financial Sciences, University of Petra, Jordan
mohammad197119@yahoo.com, ORCID: (0000-0003-3513-3965)
[2]Electronic Marketing and Social Media, Economic and Administrative Sciences Zarqa University, Jordan.
3Research follower, INTI International University, 71800 Negeri Sembilan, Malaysia.
dr_sliman@yahoo.com, ORCID: (0000-0001-6156-9063)
[4]Faculty of Business and Communications, INTI International University, 71800 Negeri Sembilan, Malaysia.
[5]Shinawatra University, 99 Moo 10, Bangtoey, Samkhok, Pathum Thani 12160 Thailand
asokan.vasudevan@newinti.edu.my, ORCID: (0000-0002-9866-4045)
[6]Department of Business Administration, Collage of Business and Economics, Qassim University, Qassim, Saudi Arabia
barieny@qu.edu.sa
[7]Marketing Department, College of Business, King Saud University, Riyadh 11362, Saudi Arabia.
sualenazi@ksu.edu.s

Received: 14th Aug, 2025; Revised: 15th Sep 2025; Accepted: 14th Nov, 2025; Available Online: 30th Nov, 2025

ABSTRACT
The purpose of the paper is to critically review the application of artificial intelligence (AI) to streamline the process of nanoparticle-based drug delivery systems, and in particular to address unresolved issues in therapeutic precision, safety, and clinical translation. The research uses the secondary research methodology and will synthesise evidence of peer reviews in the fields of nanotechnology, biomedical engineering, and computational modelling. This methodology allows the thorough assessment of various facets such as selection of nanoparticles material, optimization of particle size and shape, mode of surface functionalization, drug loading ability, controlled release prediction, targeting ligand design, analysis of cellular uptake pathway, prediction of pharmacokinetics, modeling of biodistribution, toxicity and biocompatibility, tumor microenvironment responsiveness, formulation optimization using AI, in vivo performance, real-time monitoring of delivery algorithms, personalized treatment, and optimization. According to the literature, it is constantly emphasised that AI will improve the accuracy of prediction, variability reduction, and speed up the design by combining multi-scale models, machine learning, and real-time monitoring. The results indicate that AI-based systems enhance drug encapsulation, can design targeted ligands, can simulate the biodistribution, and personalise treatment plans, thus closing the gap between laboratory innovations and clinical practice. Nevertheless, there are still issues in data heterogeneity, regulatory.
Keywords: Drug delivery, nanoparticle material, particle size, surface functionalization, targeting ligand, drug loading, controlled release, tumour microenvironment, pharmacokinetics prediction, biodistribution modelling
How to cite this article: Mohammad AAS, Mohammad SI, Vasudevan A, Al Oraini B, Alenazi SA.; AI-Driven Optimisation of Nanoparticle-Based Drug Delivery Systems. Int J Drug Deliv Technol. 2025;15(4): 1956-1963, DOI: 10.25258/ijddt.15.4.51
Source of support: Nil.
Conflict of interest: None

INTRODUCTION

Drug delivery systems based on nanoparticles have become a revolution in contemporary treatment methods, where they deliver controlled release and targeted delivery of drugs with enhanced bioavailability. Nevertheless, their clinical implementation still has continued challenges that include patient response heterogeneity, erratic pharmacokinetics and production scaling problems. Artificial intelligence (AI) is also becoming cultivated as one of the strong means to streamline these systems through the combination of computational modelling, predictive analytics, and machine learning algorithms. Recent research shows that artificial intelligence-based models can quickly design nanoparticles by modelling the best sizes, surface charge and ligand density to increase cellular uptake and reduce off-target effects[1,2,3]

**Author for Correspondence: mohammad197119@yahoo.com*



Figure 1: Challenges of drug delivery in the current market[1]

As an illustration, adaptive neuro-fuzzy inference systems and multilayer perceptron neural networks have been used to simulate drug release kinetics and to optimise formulations of nanovectors. The application of AI to guide the design of nanoparticles in cancer treatment has enhanced tumour targeting through the analysis of massive amounts of patient-specific biomarkers and the optimisation of drug release profiles. Regardless of these developments, there are still specific issues: nanoparticles tend to be deposited in the non-target organs, liver, and spleen, causing toxicity; the tumour microenvironment varies, making drug penetration more complicated; and regulatory barriers have slowed the clinical implementation. AI provides solutions through simulating biological interactions, toxicity patterns, and the use of personalized nanomedicine approaches[4,5,6]. Therefore, the combination of AI and nanoparticle-based drug delivery is not only a technological breakthrough but also a reasonable solution to the previously existing obstacles in drug development, filling the

Literature Review

Artificial intelligence (AI) converging with nanoparticle-based drug delivery systems has become a core theme of recent research in the biomedical field, and several studies have highlighted its potential to transform numerous therapeutic fields. AI optimisation also allows balancing the parameters of nanoparticles (particle size, surface charge, and ligand density) with precision, thus enhancing the kinetics of drug release and reducing off-target toxicity[7] Das (2023) generalises this view of cancer treatment, where AI-assisted nanoparticle design can be used to augment tumour-specific targeting, based on patient bio-marker sets and predict drug penetration in heterogeneous tumour micro-environments, whereas there are still issues with systemic toxicity and regulation[8]. The importance of multi-scale modelling coupled with machine learning that enables simulating nanoparticle-cell interactions on a molecular, cellular, and tissue scale, thus filling the gap between laboratory design and clinical translation in nano-cancer therapeutics[9]. Oncology is not the only branch where nanoparticle-based systems prove to be clinically useful, as AI-aided formulation design creates better retention of drugs in periodontal pockets and patient compliance with therapy, which can be seen as a sign of the versatility of these systems in chronic disease management[10]. The idea of brain-specific delivery with AI-based nanorobotics and note that intelligent nanoparticles are capable of circumnavigating the blood-brain barrier and arriving at their site of action, which is a decisive advance in the neurodegenerative disease and central nervous system pathology[11]. Taken together, these studies point to the same reasoning, namely, that the AI can not only speed up the nanoparticle design process but also tackle longstanding issues of unpredictable pharmacokinetics, organ-level accumulation, and individual patient variability. They warn that clinical translation involves strong validation systems, ethics and scalable production procedures. In such a way, AI-driven nanoparticle optimisation becomes a prospective direction and realistic solution to the traditional obstacles in the field of drug delivery.

Method

The research paper is based on the secondary method. It uses peer-reviewed articles, systematic reviews, and published data to explore AI-enhanced optimisation of nanoparticle delivery systems of drugs. The choice of secondary methods is also explained by the complexity of the subject matter, which is multidisciplinary, and the available evidence in nanotechnology, biomedical engineering and computational modelling forms a strong basis for synthesis. Secondary data allows covering a wide variety of aspects, including material selection, particle size optimisation, surface functionalization, drug loading efficiency, pharmacokinetics prediction, and toxicity assessment, not limited to laboratory experimentation. It also enables triangulation of results on oncology, neurology and periodontal applications, which are reliable and broad-based. The study combines published findings to establish patterns, gaps, and novel trends in AI-assisted formulation optimisation, in vivo simulation, and individualised treatment plans. This methodology is efficient and ethical, and relevant to the context, thus appropriate in the development of theoretical and applied knowledge in nanomedicine.

Results

Nanoparticle Material Selection and Particle Design

Drug delivery optimisation is based on the choice of an appropriate nanoparticle material. Polymeric carriers, e.g., PLGA and chitosan, are biodegradable and can be tuned to degrade quickly, whereas lipid-based systems, e.g., liposomes, are highly biocompatible and are effective encapsulators[12,13]. Imaging and theranostic functions are provided by metallic nanoparticles, such as gold and iron oxide, but with increased toxicity.

Table 1. Nanoparticle Material Selection and Particle Design

Material Type	Degradation Half-Life (hrs)	Encapsulation Efficiency (%)	Optimal Particle Size (nm)	Shape Stability Index (0–1)
Polymeric (PLGA)	48	82	120	0.85
Liposomal	36	90	100	0.92
Metallic (Gold NP)	72	65	80	0.78
Hybrid Composite	60	88	110	0.89



Figure 2: Nanoparticle Material Selection and Particle Design

Artificial intelligence (AI) guided material selection combines sets of degradation kinetics, toxicity screening, and encapsulation efficiency to inform the most appropriate carrier of a particular drug. The size and shape of a particle are also important: smaller particles (less than 100 nm) increase tumour penetration, whereas rod-shaped or disc-shaped geometry enhances circulation and cellular uptake. Computational models are simulations of the effects of geometry on biodistribution, which predict organ-level accumulation and clearance routes[14,15,16]. It has been demonstrated that there is a tendency for prolonged systemic circulation by the use of spherical particles, but the elongated particles take advantage of the amplified permeability and retention effects within tumours. Material selection with AI-informed particle design offers researchers a chance to balance stability, biocompatibility, and therapeutic efficacy to solve long-standing issues of unpredictable pharmacokinetics and systemic toxicity.

Surface Functionalization and Targeting Ligand Strategies

Nanoparticles are converted into smart carriers in surface engineering. PEGylation decreases immune clearance, and cationic endocytosis improves endocytosis. Algorithms developed by AI consider the density of ligands, charge distribution, and hydrophilicity to maximise the ability of cells to take them in[17,18]. Ligands are modelled to bind with affinity to tumour-specific receptors, e.g. folate, transferrin and antibodies to ensure specific delivery.

Table 2. Surface Functionalization and Targeting Ligand Strategies

Functionalization Type	Ligand Density (μmol/cm²)	Binding Affinity (Kd, nM)	Immune Clearance Reduction (%)	Cell Uptake Efficiency (%)
PEGylation	2.5	15	70	65
Folate Ligand	3.2	10	55	80
Transferrin Ligand	2.8	8	60	78
Antibody Conjugation	4.0	5	75	85



Figure 3: Surface Functionalization and Targeting Ligand Strategies

The deep learning models can anticipate the interactions of ligand and receptor, considering the varied patient biomarker phenotype, which allows the targeted treatment of each patient. Surface functionalization also affects the prediction of pharmacokinetics and modelling of biodistribution, which decreases the off-target deposition in the liver and spleen. Immune recognition and complement activation simulations can be used to increase the toxicity and biocompatibility assessment. It has been demonstrated that nanoparticles with optimal ligand density are more tumour microenvironment responsive and can penetrate hypoxic or acidic niches more easily[19,20]. The AI-directed ligand design is therefore a bridging step in theoretical modelling and clinical translation, providing a customised topology of the surfaces to achieve maximum therapeutic index and low toxicity to the systemic system.

Drug Loading Efficiency and Controlled Release Prediction

Therapeutic payload is defined by drug loading efficacy, and sustained efficacy is defined by controlled release. The encapsulation methodologies are different: hydrophobic drugs become a part of polymeric networks, and hydrophilic molecules are surrounded by liposomal cores[21,22]. AI models are used to model the interaction of drugs and carriers, which determines the encapsulation efficiency and stability under physiological conditions. The prediction of controlled drug release is done using machine learning that is trained using in vitro release profiles to predict behaviour in vivo with changes in enzymatic degradation, pH, and temperature.

Table 3. Drug Loading Efficiency and Controlled Release Prediction

Drug Type	Loading Capacity (mg/g NP)	Release Half-Time (hrs)	pH-Triggered Release (%)	Microenvironment Responsiveness Index (0–1)
Hydrophobic (Paclitaxel)	120	48	65	0.82
Hydrophilic (Doxorubicin)	95	36	72	0.88
Peptide Drug	80	24	55	0.76
siRNA Payload	60	30	68	0.84



Figure 4: Drug Loading Efficiency and Controlled Release Prediction

Smart nanoparticles can improve microenvironment responsiveness of tumours by being engineered to release drugs when subjected to acidic or hypoxic environments, and AI predicts the threshold conditions. Cellular uptake pathway analysis combines data on diffusion, endocytosis and exocytosis to optimise release schedules. The fact that nanoparticles have the capability to be delivered to tumour tissues via pH-sensitive coating at the expense of healthy cells indicates that evidence supports the first hypothesis[23,24]. Integrating the modelling of the drug loading efficiency with the controlled release prediction, AI minimises the variability of therapeutic outcome and enhances patient compliance, plus increases the speed of regulatory approval with reproducible performance data.

In Vivo Performance Simulation and Real-Time Monitoring

The in vivo performance simulation combines the pharmacokinetics, biodistribution and toxicity information with the predictive schemes. AI models can model the circulation of nanoparticles and clearance of nanoparticles, and accumulation at the organ level, taking into consideration patient-specific factors, including age, metabolism, and disease condition. Biodistribution modelling is used to predict the fate of nanoparticles, and thus cause less accumulation unintentionally in the liver or spleen[25]. Computational immune response simulations improve toxicity and biocompatibility analysis, predicting cytokine release and safety over the long term.

Table 4. In Vivo Performance Simulation and Real-Time Monitoring

Simulation Parameter	Circulation Time (hrs)	Organ Accumulation (%)	Toxicity Score (0–10)	Real-Time Monitoring Accuracy (%)
Standard Polymeric NP	12	25	3	85
Liposomal NP	18	20	2	90
Metallic NP	24	40	6	78
Hybrid NP	20	22	4	88

Nanoparticle behavior can be monitored in real-time with algorithms of delivery monitoring based on imaging modalities such as MRI or fluorescence. It is demonstrated that AI-controlled surveillance can modify the delivery of drugs on the fly, designing adaptive systems. Simulations of the penetration of nanoparticles in heterogeneous tissue also confirm tumour microenvironment responsiveness. A feedback loop process is therefore generated by in vivo performance simulation, in which predictor models are used to guide design corrections to minimise failure in clinical trials and speed up translation.

Personalized Treatment Optimization through AI-Driven Nanomedicine

The final border is the optimisation of personalised treatment. AI combines patient-specific omics data, genomics, proteomics, and metabolomics data with nanoparticle design to shape drug release profiles individually using patient signatures. Pharmacokinetics prediction is made patient-specific, as dosing regulations change with metabolic variations[26]. Biodistribution modelling uses anatomic and physiological variations in the system to ensure a focused delivery in varied groups of people.

Table 5. Personalized Treatment Optimization through AI-Driven Nanomedicine

Patient Profile	Predicted Optimal Dose (mg/kg)	Personalised Release Rate (µg/hr)	Immune Compatibility (%)	Therapeutic Response Probability (%)
Oncology Patient A	2.5	120	85	78
Oncology Patient B	3.0	140	80	82
Neurology Patient C	1.8	100	88	75
Periodontal Patient D	2.2	110	90	80

Figure 5: Personalized Treatment Optimization through AI-Driven Nanomedicine



The immune responses of each patient are simulated, and thus the toxicity and biocompatibility assessment becomes a personalised treatment. Tumour microenvironment responsiveness is optimised based on analysis of biomarker heterogeneity, the prediction of nanoparticle penetration in resistant niches. The adaptive feedback offered by monitoring algorithms in real-time controls the dynamical drug release rate[26]. It has been demonstrated that personalized nanomedicine decreases the adverse effects and maximizes efficacy by matching nanoparticle behavior with patient biology. Optimisation of formulation through AI therefore makes drug delivery precision therapeutics, mediating laboratory design and individualised clinical use.

Discussion

The results of AI optimisation of nanoparticle-based drug delivery systems indicate both a high level of development and a lack of it. Although the methods of predictive modelling have progressed in terms of material selection, optimisation of particle size and shape, and surface functionalization, translation of these designs to clinically viable formulations is complicated. The AI-assisted drug loading performance modelling and controlled drug release prediction show great promise in reducing variability and improving tumour microenvironment responsiveness, though there is a strong dependency on high-quality datasets, which are usually scarce or heterogeneous. Equally, personalised precision is provided by ligand design and cellular uptake pathway analysis, but individual expression of receptors in different patients makes them inapplicable in a generalised manner. The prediction of pharmacokinetics and biodistribution modelling can give useful information about the systemic circulation and organ-level accumulation, but the simulation of the performance in vivo still does not manage to obtain all the biological complexity. Delivery monitoring algorithms in real time and optimisation of treatments that are customised are potential revolutionary changes in adaptive nanomedicine, although ethical and regulatory and scaling concerns are still unclear. More importantly, the issue of toxicity and biocompatibility should be given the top priority since even slight changes in the behavior of nanoparticles can have an undesirable impact. On the whole, AI can make the process more efficient, personalised, and predictive, yet its application requires a combination of computational knowledge and experimental validation, regulations, and patient-specific data to provide safe, reproducible and clinically impactful findings.

Conclusion

It can be concluded that artificial intelligence, when paired with the use of nanoparticles to deliver drugs, is a breakthrough in precision medicine. The artificial intelligence-based systems tackle the persistent challenges of unpredictability and ineffectiveness of traditional nanomedicine by systematically addressing the material selection, optimisation of particle size and shape, functionalizing surfaces, drug loading, and predictive release. It is proven that computational modelling increases designing ligand targets, cellular uptake pathway modelling, pharmacokinetics modeling, and biodistribution molecular modelling and toxicity assessment, guarantee safety and biocompatibility. In addition, the responsiveness of the tumor microenvironment and in vivo performance simulation demonstrates the adaptability of AI-controllable nanoparticles to complicate biological environments. The algorithms of real-time monitoring of delivery and personalized treatment optimization form a feedback loop that allows applying individual therapeutic strategies with fewer adverse outcomes. Altogether, these results confirm that the synthesis of secondary research is a strong evidence

of the transformative potential of AI, which may support laboratory innovation with clinical translation and open the path to scalable and patient-specific nanomedicine-based solutions.

Acknowledgement
This research is funded by Zarqa University.

REFERENCE

1. Vora LK, Gholap AD, Jetha K, Thakur RR, Solanki HK, Chavda VP. Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics. 2023;15(7):1916. doi:10.3390/pharmaceutics15071916.
2. Nasir J, Ibrahim RM, Sarwar MA, Sarwar B, Al-Rahmi WM, Alturise F, et al. The effects of transformational leadership, organizational innovation, work stressors, and creativity on employee performance in SMEs. Front Psychol. 2022; 13:772104.
3. Mohammad AA. The impact of COVID-19 on digital marketing and marketing philosophy: evidence from Jordan. Int J Bus Inf Syst. 2025;48(2):267–281.
4. Bernad ES, Vasilache IA, Bernad RL, Hogea L, Ene D, Duica F, et al. Extracellular vesicles and nanoparticles in regenerative and personalised medicine: diagnostic and therapeutic roles—a narrative review. Pharmaceutics. 2025;17(10):1331. doi:10.3390/pharmaceutics17101331.
5. Bhat AA, Mir AA, Allie AH, Lone MA, Al-Adwan AS, Jamali D, et al. Unlocking corporate social responsibility and environmental performance: mediating role of green strategy, innovation, and leadership. Innov Green Dev. 2024;3(2):100112.
6. Mohammad AA, Al-Daoud KI, Al-Daoud SI, Samarah TA, Vasudevan A, Li M. Content marketing optimization: A/B testing and conjoint analysis for engagement strategies in Jordan. J Ecohumanism. 2024;3(7):3086–3099.
7. Kapoor DU, Sharma JB, Gandhi SM, Prajapati BG, Thanawuth K, Limmatvapirat S, et al. AI-driven design and optimization of nanoparticle-based drug delivery systems. Sci Eng Health Stud. 2024;18:24010003–3. doi:10.69598/sehs.18.24010003.
8. Das KP. Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: current progress and challenges. Front Med Technol. 2023;4:1067144. doi:10.3389/fmedt.2022.1067144.
9. Debnath G, Vasu B, Gorla RS. Current state-of-the-art in multi-scale modeling in nano-cancer drug delivery: role of AI and machine learning. Cancer Nanotechnol. 2025;16(1):45. doi:10.1186/s12645-025-00326-1.
10. Alavi SE, Ebrahimi Shahmabadi H, Sharma LA, Sharma A. Nanoparticle-based drug delivery systems for non-surgical periodontal therapy: innovations and clinical applications. 3 Biotech. 2025;15(8):269. doi:10.1007/s13205-025-04443-x.
11. Rai A, Shah K, Dewangan HK. Review on the artificial intelligence-based nanorobotics targeted drug delivery system for brain-specific targeting. Curr Pharm Des. 2023;29(44):3519–3531. doi:10.2174/0113816128279248231210172053.
12. Mahar R, Chakraborty A, Nainwal N, Bahuguna R, Sajwan M, Jakhmola V. Application of PLGA as a biodegradable and biocompatible polymer for pulmonary delivery of drugs. AAPS PharmSciTech. 2023;24(1):39. doi:10.1208/s12249-023-02502-1.
13. Albelbisi NA, Al-Adwan AS, Habibi A. Self-regulated learning and satisfaction: key determinants of MOOC success. Educ Inf Technol. 2021;26(3):3459–3481.
14. Zhao J, Zhao S, Luding S. The role of particle shape in computational modelling of granular matter. Nat Rev Phys. 2023;5(9):505–525. doi:10.1038/s42254-023-00617-9.
15. Mohammad AA, Al-Daoud KI, Rusho MA, Alkhayyat A, Doshi H, Dey P, et al. Modeling polyethylene glycol density using robust soft computing methods. Microchem J. 2025;210:112815.
16. Jermy BR, Ravinayagam V, Almohazey D, Alamoudi WA, Dafalla H, Akhtar S, et al. PEGylated green halloysite/spinel ferrite nanocomposites for pH sensitive delivery of dexamethasone: a potential pulmonary drug delivery treatment option for COVID-19. Appl Clay Sci. 2022;216:106333. doi:10.1016/j.clay.2021.106333.
17. Jermy BR, Ravinayagam V, Almohazey D, Alamoudi WA, Dafalla H, Akhtar S, et al. PEGylated green halloysite/spinel ferrite nanocomposites for pH sensitive delivery of dexamethasone: a potential pulmonary drug delivery treatment option for COVID-19. Appl Clay Sci. 2022;216:106333. doi:10.1016/j.clay.2021.106333.
18. Mohammad AA, Nijalingappa Y, Mohammad SI, Natarajan R, Lingaraju L, Vasudevan A, et al. Fuzzy linear programming for economic planning and optimization: a quantitative approach. Cybern Inf Technol. 2025;25(2).
19. Ugwu CE, Oraeluno JN, Eze KC, Ezenma CO, Nwankwo AO. PEGylated aceclofenac solid lipid microparticles homolipid-based solidified reverse micellar solutions for drug delivery. Heliyon. 2022;8(4):e09247. doi:10.1016/j.heliyon.2022.e09247.
20. Mohammad AA, Mohammad SI, Al-Daoud KI, Al

Oraini B, Qurneh M, Vasudevan A, Wang Y. Digital platforms and agricultural marketing: bridging gaps between farmers and consumers in Jordan. Res World Agric Econ. 2025;740–756.

21. Rana MM, De la Hoz Siegler H. Evolution of hybrid hydrogels: next-generation biomaterials for drug delivery and tissue engineering. Gels. 2024;10(4):216. doi:10.3390/gels10040216.
22. Mohammad AA, Mohammad SI, Al Oraini B, Vasudevan A, Hindieh A, Altarawneh A, et al. Strategies for applying interpretable and explainable AI in real world IoT applications. Discover Internet Things. 2025;5(1):71.
23. Li B, Shao H, Gao L, Li H, Sheng H, Zhu L. Nano-drug co-delivery system of natural active ingredients and chemotherapy drugs for cancer treatment: a review. Drug Deliv. 2022;29(1):2130–2161. doi:10.1080/10717544.2022.2094498.
24. Mohammad AA, Mohammad SI, Al-Oraini B, Vasudevan A, Hunitie MF, Ismael B. The impact of agricultural credit on farm productivity, employment, and rural development: empirical evidence from Jordan's agricultural sector. Pak J Agric Res. 2025;38(3):20–31.
25. Mikayilov E, Zeynalov N, Taghiyev D, Taghiyev S. Role of computational modeling in the design and development of nanotechnology-based drug delivery systems. Chem Biochem Eng Q. 2024;38(2):97–110. doi:10.15255/CABEQ.2024.2290.
26. Arav Y. Advances in modeling approaches for oral drug delivery: artificial intelligence, physiologically-based pharmacokinetics, and first-principles models. Pharmaceutics. 2024;16(8):978. doi:10.3390/pharmaceutics16080978..